Bee venom allergy vaccine - Allergopharma

Drug Profile

Bee venom allergy vaccine - Allergopharma

Latest Information Update: 13 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergopharma
  • Class Antiallergics; Hymenoptera allergy immunotherapies; Immunotherapies; Venoms
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Bee venom hypersensitivity

Most Recent Events

  • 13 Aug 2015 No recent reports on development identified - Phase-III for Bee venom hypersensitivity (Prevention) in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top